The challenge of choosing in cardiovascular risk management

Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide. For many years guidelines have listed optimal preventive therapy. More recently, novel therapeutic options have broadened the options for state-of-the-art CV risk management (CVRM). In the majority of patients with C...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Netherlands heart journal Ročník 30; číslo 1; s. 47 - 57
Hlavní autori: Hoogeveen, R. M., Hanssen, N. M. J., Brouwer, J. R., Mosterd, A., Tack, C. J., Kroon, A. A., de Borst, G. J., ten Berg, J., van Trier, T., van Lennep, J. Roeters, Liem, A., Serné, E., Visseren, F. L. J., Cornel, J. H., Peters, R. J. G., Jukema, J. W., Stroes, E. S. G.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Houten Bohn Stafleu van Loghum 01.01.2022
Springer Nature B.V
Predmet:
Acute coronary syndromes
Atherosclerosis
Cardiology
Cardiovascular disease
Decision making
Disease prevention
Health risks
Medical Education
Medicine
Medicine & Public Health
Mortality
Review
Review Article
Prevention
Drugs
Cardiovascular risk management
Cardiovascular disease
Novel interventions
Atherosclerosis
ISSN:1568-5888, 1876-6250
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide. For many years guidelines have listed optimal preventive therapy. More recently, novel therapeutic options have broadened the options for state-of-the-art CV risk management (CVRM). In the majority of patients with CVD, risk lowering can be achieved by utilising standard preventive medication combined with lifestyle modifications. In a minority of patients, add-on therapies should be considered to further reduce the large residual CV risk. However, the choice of which drug combination to prescribe and in which patients has become increasingly complicated, and is dependent on both the absolute CV risk and the reason for the high risk. In this review, we discuss therapeutic decisions in CVRM, focusing on (1) the absolute CV risk of the patient and (2) the pros and cons of novel treatment options.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1568-5888
1876-6250
DOI:10.1007/s12471-021-01599-y